• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ProQR Therapeutics N.V. (Amendment)

    2/9/23 5:00:26 PM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRQR alert in real time by email
    SC 13G/A 1 tm235875d1_sc13ga.htm SC 13G/A

     

     

     

      UNITED STATES  
      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 19341
    (Amendment No. 4)*

     

    ProQR Therapeutics N.V. 

    (Name of Issuer)

     

    Ordinary Shares, nominal value €0.04 per share

    (Title of Class of Securities)

     

    N71542109

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

       

     

     

    CUSIP No. N71542109

     

      1 Name of Reporting Persons
    Stichting Aescap Life Sciences
     
      2 Check the Appropriate Box if a Member of a Group
        (a) ¨
        (b) ¨
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization
    The Netherlands

     

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    4,765,659
     
    6 Shared Voting Power
    0
     
    7 Sole Dispositive Power
    4,765,659
     
    8 Shared Dispositive Power
    0

     

     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person
    4,765,659
     
      10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9)
    6.7%
     
      12 Type of Reporting Person (See Instructions)
    FI

     

     

    (1) Based upon 71,433,806 ordinary shares outstanding as of September 30, 2022, as disclosed in the Issuer’s Report of Foreign Private Issuer on Form 6-K filed on November 9, 2022.

     

       

     

     

      1 Name of Reporting Persons
    Privium Fund Management B.V.
     
      2 Check the Appropriate Box if a Member of a Group
        (a) ¨
        (b) ¨
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization
    The Netherlands

     

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    4,765,659
     
    6 Shared Voting Power
    0
     
    7 Sole Dispositive Power
    5,344,446
     
    8 Shared Dispositive Power
    0

     

     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person
    5,344,446
     
      10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9)
    7.5%
     
      12 Type of Reporting Person (See Instructions)
    FI

     

     

    (1) Based upon 71,433,806 ordinary shares outstanding as of September 30, 2022, as disclosed in the Issuer’s Report of Foreign Private Issuer on Form 6-K filed on November 9, 2022

     

       

     

       

    CUSIP No. N71542109

     

      1 Name of Reporting Persons
    Stichting Aescap Genetics
     
      2 Check the Appropriate Box if a Member of a Group
        (a) ¨
        (b) ¨
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization
    The Netherlands

     

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    578,787
     
    6 Shared Voting Power
    0
     
    7 Sole Dispositive Power
    578,787
     
    8 Shared Dispositive Power
    0

     

     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person
    578,787
     
      10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9)
    0.8%
     
      12 Type of Reporting Person (See Instructions)
    FI

     

     

    (1) Based upon 71,433,806 ordinary shares outstanding as of September 30, 2022, as disclosed in the Issuer’s Report of Foreign Private Issuer on Form 6-K filed on November 9, 2022.

     

       

     

     

    CUSIP No. N71542109

     

      1 Name of Reporting Persons
    Inspirational Visions BV
     
      2 Check the Appropriate Box if a Member of a Group
        (a) ¨
        (b) ¨
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization
    The Netherlands

     

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    35,411
     
    6 Shared Voting Power
    0
     
    7 Sole Dispositive Power
    35,411
     
    8 Shared Dispositive Power
    0

     

     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person
    35,411
     
      10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9)
    0.1%
     
      12 Type of Reporting Person (See Instructions)
    FI

     

     

    (1) Based upon 71,433,806 ordinary shares outstanding as of September 30, 2022, as disclosed in the Issuer’s Report of Foreign Private Issuer on Form 6-K filed on November 9, 2022

     

       

     

       

      1 Name of Reporting Persons
    Patrick Johan Hendrik Krol
     
      2 Check the Appropriate Box if a Member of a Group
        (a) ¨
        (b) ¨
     
      3 SEC Use Only
     
      4 Citizenship or Place of Organization
    The Netherlands

     

         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
    5,406,159
     
    6 Shared Voting Power
    0
     
    7 Sole Dispositive Power
    5,406,159
     
    8 Shared Dispositive Power
    0

      

     
      9 Aggregate Amount Beneficially Owned by Each Reporting Person
    5,406,159
     
      10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
     
      11 Percent of Class Represented by Amount in Row (9)
    7.6%
     
      12 Type of Reporting Person (See Instructions)
    IN

     

     

    (1) Based upon 71,433,806 ordinary shares outstanding as of September 30, 2022, as disclosed in the Issuer’s Report of Foreign Private Issuer on Form 6-K filed on November 9, 2022.

     

       

     

     

    Item 1. (a). Name of Issuer
    ProQR Therapeutics N.V. (the “Issuer”)
      (b). Address of Issuer’s Principal Executive Offices:
    Zernikedreef 9, 2333 CK Leiden, The Netherlands
       
    Item 2(a). Name of Person Filing
       
    Item 2(b). Address of Principal Business Office
    Item 2(c).

    Citizenship

    (i) Stichting Aescap Life Sciences (“Aescap Life Sciences”)

    Gustav Mahlerplein 3

    1082 MS Amsterdam

    The Netherlands

    Citizenship: The Netherlands

     

    (ii) Privium Fund Management B.V. (“Privium”), as the fund manager of Aescap Life Sciences

    Gustav Mahlerplein 3

    1082 MS Amsterdam

    The Netherlands

    Citizenship: The Netherlands

     

    (iii) Stichting Aescap Genetics (“Aescap Genetics”)

    Gustav Mahlerplein 3

    1082 MS Amsterdam

    The Netherlands

    Citizenship: The Netherlands

     

    (iv) Inspirational Visions BV (“Inspirational Visions”)

    A.J. Ernststraat 595-C
    1082 LN Amsterdam
    The Netherlands
    Citizenship: The Netherlands

     

    (v) Patrick Johan Hendrik Krol (“Krol”), the portfolio manager for Privium and Aescap Genetics and the managing director of Inspirational Visions

    Gustav Mahlerplein 3

    1082 MS Amsterdam

    The Netherlands

    Citizenship: The Netherlands

     

    The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”

    Item 2(d). Title of Class of Securities:
    Ordinary Shares, nominal value €0.04 per share (the “Shares”)
    Item 2(e). CUSIP Number:
    N71542109

     

       

     

     

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
       
      This Item 3 is not applicable.
       
    Item 4. Ownership.
       
      (a)

    Amount beneficially owned:

     

    As its Fund Manager, the Shares held by Aescap Life Sciences may be deemed to be beneficially owned by Privium. In addition, as its Fund Manager, the Shares held by Aescap Genetics may be deemed to be beneficially owned by Privium. As the portfolio manager of Privium, Krol may be deemed to beneficially own the Shares held by Aescap Life Sciences. In addition, as the managing director of Inspirational Visions, Krol may be deemed to beneficially own the Shares held by Inspirational Visions.

     

    As of the date of this report, Aescap Life Sciences directly held 4,765,659 Shares. As of the date of this report, Aescap Genetics directly held 578,787 Shares. As of the date of this report, Inspirational Visions directly held 35,411 Shares. As of the date of this report, Krol directly held 26,302 Shares.

      (b)

    Percent of class:

     

    Aescap Life Sciences may be deemed the beneficial owner of approximately 6.7% of the Shares outstanding.

     

    Privium may be deemed the beneficial owner of approximately 7.5% of the Shares outstanding.

     

    Aescap Genetics may be deemed the beneficial owner of approximately 0.8% of the Shares outstanding.

     

    Inspirational Visions may be deemed the beneficial owner of approximately 0.1% of the Shares outstanding.

     

    Krol may be deemed the beneficial owner of approximately 7.6% of the Shares outstanding.

      (c)

    Number of shares as to which the Reporting person has:

     

        Aescap Life Sciences:
        (i)

    Sole power to vote or to direct the vote:

    4,765,659

        (ii)

    Shared power to vote or to direct the vote:

    0

        (iii)

    Sole power to dispose or to direct the disposition of:

    4,765,659

        (iv)

    Shared power to dispose or to direct the disposition of:

    0

        Privium:
        (i)

    Sole power to vote or to direct the vote:

    5,344,446

        (ii)

    Shared power to vote or to direct the vote:

    0

        (iii)

    Sole power to dispose or to direct the disposition of:

    5,344,446

        (iv)

    Shared power to dispose or to direct the disposition of:

    0

     

       

     

     

        Aescap Genetics:
        (i)

    Sole power to vote or to direct the vote:

    578,787

        (ii)

    Shared power to vote or to direct the vote:

    0

        (iii)

    Sole power to dispose or to direct the disposition of:

    578,787

        (iv)

    Shared power to dispose or to direct the disposition of:

    0

        Inspirational Visions:
        (i)

    Sole power to vote or to direct the vote:

    35,411

        (ii)

    Shared power to vote or to direct the vote:

    0

        (iii)

    Sole power to dispose or to direct the disposition of:

    35,411

        (iv)

    Shared power to dispose or to direct the disposition of:

    0

        Krol:
        (i)

    Sole power to vote or to direct the vote:

    5,406,159

        (ii)

    Shared power to vote or to direct the vote:

    0

        (iii)

    Sole power to dispose or to direct the disposition of:

    5,406,159

        (iv)

    Shared power to dispose or to direct the disposition of:

    0

     

    Item 5. Ownership of Five Percent or Less of a Class
       
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
    This Item 6 is not applicable.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
       
    This Item 7 is not applicable.
     
    Item 8. Identification and Classification of Members of the Group.
       
    This Item 8 is not applicable.
     
    Item 9. Notice of Dissolution of Group.
       
    This Item 9 is not applicable.

     

       

     

     

    Item 10. Certification.
       

    Each of the Reporting Persons hereby makes the following certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    STICHTING AESCAP LIFE SCIENCES  
       
    BY: PRIVIUM FUND MANAGEMENT B.V., ITS FUND MANAGER
         
    By: /s/ Patrick Johan Hendrik Krol  
    Name: P.J.H. Krol  
    Title: Portfolio Manager  
         
    STICHTING AESCAP GENETICS  
       
    BY: PRIVIUM FUND MANAGEMENT B.V., ITS FUND MANAGER
         
    By: /s/ Patrick Johan Hendrik Krol  
    Name: P.J.H. Krol  
    Title: Portfolio Manager  
       
    PRIVIUM FUND MANAGEMENT B.V.  
         
    By: /s/ Patrick Johan Hendrik Krol  
    Name: P.J.H. Krol  
    Title: Portfolio Manager  
       
    INSPIRATIONAL VISIONS B.V.  
         
    By: /s/ Patrick Johan Hendrik Krol  
    Name: P.J.H. Krol  
    Title: Managing Director  
       
    PATRICK JOHAN HENDRIK KROL  
         
      /s/ Patrick Johan Hendrik Krol  
         
    Dated: February 9, 2023  

     

       

    Get the next $PRQR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRQR

    DatePrice TargetRatingAnalyst
    4/29/2025$5.00Outperform
    Evercore ISI
    4/29/2025$8.00Overweight
    Cantor Fitzgerald
    3/10/2025$4.00Neutral → Buy
    Citigroup
    1/10/2025$15.00Outperform
    Oppenheimer
    10/29/2024$6.00 → $14.00Outperform → Strong Buy
    Raymond James
    11/8/2023$2.00Neutral → Buy
    Chardan Capital Markets
    3/30/2023$1.50 → $5.00Mkt Perform → Mkt Outperform
    JMP Securities
    12/22/2022$0.80 → $5.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PRQR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

      LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will present at two upcoming scientific conferences: the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, taking place May 13-17, 2025, in New Orleans, Louisiana and the TIDES USA 2025: Oligonucleotide and Peptide Therapeutics Conference, being held May 19-22, 2025, in San Diego, California. "We are excited to share these presentations with the scientific community, demonstrating the breadt

      5/12/25 8:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProQR Announces First Quarter 2025 Operating and Financial Results

      Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief Medical Officer€ 132.4 million cash and cash equivalents as of end Q1 providing runway into mid-2027, plus additional potential milestones from Lilly partnership LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today r

      5/8/25 7:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

      LEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform today announced that Company management is scheduled to present at the Citizens (JMP) Life Sciences Conference in New York City on Thursday, May 8 at 11:30 AM EDT. A live webcast of the Company's fireside chat will be available from the "Investors & Media" section of ProQR's website under "Events". A replay of the webcast will then be available for approximately 30 days. About Axiomer™ ProQR is pioneering a next-generation RNA base

      5/2/25 8:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRQR
    Financials

    Live finance-specific insights

    See more
    • ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

      LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.  During the event, ProQR will highlight its proprietary Axiomer™ ADAR-mediated RNA editing platform, along with updates on its pipeline of development candidates including data updates and next steps on its programs for NTCP and B4GALT1, AX-0810 and AX-1412. Prese

      12/5/24 8:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases

      ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company's AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT Annual MeetingManagement webinar May 9, 2024 at 8:00 am EDT LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced new preclinical data for its proprietary Axiomer™ RNA editing technology platform, incl

      5/8/24 8:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

      LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and webcast to discuss the Company's Axiomer RNA editing technology platform following the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am EST.  The live and archived webcast of the presentation will be accessible through this webcast link, or to access the live call by phone please register here. A dial-in and unique PIN will be provided to join the call. The

      12/22/22 6:15:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRQR
    SEC Filings

    See more
    • SEC Form 6-K filed by ProQR Therapeutics N.V.

      6-K - ProQR Therapeutics N.V. (0001612940) (Filer)

      6/3/25 4:11:07 PM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ProQR Therapeutics N.V.

      SCHEDULE 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)

      5/12/25 9:07:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ProQR Therapeutics N.V.

      6-K - ProQR Therapeutics N.V. (0001612940) (Filer)

      5/8/25 7:00:17 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRQR
    Leadership Updates

    Live Leadership Updates

    See more
    • ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

      LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dennis Hom as Chief Financial Officer (CFO) and Cristina Lopez Lopez, MD, PhD, as Chief Medical Officer (CMO). These key leadership appointments support the advancement of the Company's Axiomer platform technology and pipeline of RNA editing programs as it enters the clinical stage. "We are thrilled to welcome Dennis and Cristina to ProQR at such an important time in our evolution," said Daniel A

      4/14/25 7:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

      LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term collaborator of ProQR and a valued member of ProQR's Scientific Advisory Board, where he has played an important role in shaping the Company's ADAR-based RNA editing platform. Dr. Beal's decades of res

      12/10/24 8:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board

      LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (the "Company"), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined ProQR as a strategic advisor.  "It is a great honor to have John engaged with ProQR as a strategic advisor to the Supervisory Board to support us in defining the next steps for the Company, while we continue to analyze data from the Illuminate trial of sepofarsen and identify next steps for the program, if any,"

      3/7/22 7:00:00 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRQR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ProQR Therapeutics N.V. (Amendment)

      SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)

      2/14/24 6:08:12 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ProQR Therapeutics N.V. (Amendment)

      SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)

      2/9/24 6:37:13 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ProQR Therapeutics N.V.

      SC 13G - ProQR Therapeutics N.V. (0001612940) (Subject)

      9/14/23 5:20:05 PM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRQR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on ProQR Therapeutics with a new price target

      Evercore ISI initiated coverage of ProQR Therapeutics with a rating of Outperform and set a new price target of $5.00

      4/29/25 8:12:03 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on ProQR Therapeutics with a new price target

      Cantor Fitzgerald resumed coverage of ProQR Therapeutics with a rating of Overweight and set a new price target of $8.00

      4/29/25 8:11:53 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProQR Therapeutics upgraded by Citigroup with a new price target

      Citigroup upgraded ProQR Therapeutics from Neutral to Buy and set a new price target of $4.00

      3/10/25 7:58:48 AM ET
      $PRQR
      Biotechnology: Pharmaceutical Preparations
      Health Care